1. Spyropoulos AC et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. DOI: 10.1378/chest.10-1944

2. Amin AN et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012 Mar;7(3):231-8. DOI: 10.1002/jhm.1002

3. Cohoon KP et al. Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. Am J Med. 2018 Mar;131(3):307-316.e2. DOI: 10.1016/j.amjmed.2017.09.015

4. Smeeth L et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006 Apr 1;367(9516):1075-1079. DOI: 10.1016/S0140-6736(06)68474-2

5. Schmidt M et al. Acute infections and venous thromboembolism. J Intern Med. 2012 Jun;271(6):608-18. DOI: 10.1111/j.1365-2796.2011.02473

6. Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. DOI: 10.1093/eurheartj/ehz405

7. Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge. Thromb J. 2011 Oct 13;9(1):15. DOI: 10.1186/1477-9560-9-15

8. Kahn SR et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. DOI: 10.1378/chest.11-2296

9. Spyropoulos AC et al. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis. TH Open. 2020 Mar 13;4(1):e59-e65. DOI: 10.1055/s-0040-1705137

10. Cohen AT et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11;375(6):534-44. DOI: 10.1056/NEJMoa1601747

11. Cohoon KP et al. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study. J Thromb Haemost. 2018 Jul;16(7):1278-1287. DOI: 10.1111/jth.14146.

12. Hull RD et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. DOI: 10.7326/00034819-153-1-201007060-00004

13. Cohen AT et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. DOI: 10.1056/NEJMoa1111096

14. Spyropoulos AC, Ageno W, Albers GW et al. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. DOI: 10.1056/NEJMoa1805090

15. Brighton and Sussex University Hospitals. Guidance on Thromboprophylaxis, Thrombosis and Coagulopathy Management in COVID-19 [Internet]. 2020. P. 1—13. [cited 2020 May 29]; Available from: https://www.bsuh.nhs.uk/library/wp-content/uploads/sites/8/2020/05/Covid169_Final-BSUH-COVID-Thromboprophylaxis-Thrombosis-andCoagulopathy-Guidance-v-1.1-6.pdf